Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Wall Street Zen

by · The Cerbat Gem

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Separately, D. Boral Capital reiterated a “buy” rating and set a $13.00 price target on shares of Enlivex Therapeutics in a report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Enlivex Therapeutics currently has an average rating of “Buy” and an average price target of $10.00.

Get Our Latest Analysis on ENLV

Enlivex Therapeutics Stock Up 1.0%

Shares of Enlivex Therapeutics stock opened at $1.05 on Friday. The stock has a market capitalization of $24.83 million, a P/E ratio of -1.59 and a beta of 0.83. The stock has a 50 day moving average price of $1.26 and a two-hundred day moving average price of $1.10. Enlivex Therapeutics has a 12-month low of $0.81 and a 12-month high of $2.10.

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) last issued its quarterly earnings results on Friday, May 30th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Sell-side analysts anticipate that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Enlivex Therapeutics in the fourth quarter valued at $742,000. Renaissance Technologies LLC raised its stake in shares of Enlivex Therapeutics by 112.6% in the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after purchasing an additional 84,203 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after purchasing an additional 67,886 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new position in shares of Enlivex Therapeutics in the fourth quarter valued at $26,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Enlivex Therapeutics Company Profile

(Get Free Report)

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.

Recommended Stories